Market Rumors Grow On Potential GSK Purchase Of Nanjing MeiRui Pharma For Urology Expansion In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI- Market rumors are growing that GlaxoSmithKline will add on to its urology franchise in China with a local acquisition
You may also be interested in...
GSK Finalizes Acquisition Of Nanjing Meirui For $70 Million
SHANGHAI - GlaxoSmithKline announced that the company has reached an agreement to acquire urology-dedicated Nanjing MeiRui in China for $70 million to expand its urology and over-the-counter presence in China's booming pharmaceutical market
GSK Finalizes Acquisition Of Nanjing Meirui For $70 Million
SHANGHAI - GlaxoSmithKline announced that the company has reached an agreement to acquire urology-dedicated Nanjing MeiRui in China for $70 million to expand its urology and over-the-counter presence in China's booming pharmaceutical market
Cardinal Health's Acquisition Of Zuellig Pharma Signal Of China's Intent To Allow More Foreign Investment?
SHANGHAI - In what some are calling a transformational event for the China pharma industry, Cardinal Health announced Nov. 29 that it has closed a deal to acquire local private distributor Zuellig Pharma China (Yong Yu in Chinese) for $470 million